Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)

Journal of Infection

Volumn 32, Issue 2, 1996, Pages 133-137

  Russo, R ^a   Nigro, L C ^a   Minniti, S ^a   Montineri, A ^a   Gradoni, L ^b   Caldeira, L ^c   Davidson, R N ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA; MALE; PATIENT MONITORING; RELAPSE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

EID: 0029962385     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(96)91343-2     Document Type: Review

References (21)

1. Marty P, Lelievre A, Quaranta JF, Rahal A, Gari Toussaint M, Le Fichoux Y. Use of the leishmanin skin test and Western Blot analysis for epidemiological studies in visceral leishmaniasis areas: experience in a highly endemic focus in Alpes-Maritimes (France). Trans Roy Soc Trop Med Hyg 1994; 88: 658-659.
2. Gradoni L, Gramiccia M. Leishmania Infantum tropism: strain genotype or host immune status? Parasitology Today 1994; 10: 264-267.
3. Gramiccia M, Gradoni L, Troiani M. Heterogeneity among zymodemes of Leishmania infantum from HIV-positive patients with visceral leishmaniasis in south Italy. FEMS Microbiol Letts 1995; (in press).
4. Montalban C, Callejla JL, Erice A et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect 1990; 21: 261-270.
5. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique and fact. Clin Infect Dis 1992; 14 (Suppl. 1): S114-119.
6. Berman JD. Chemotherapy for Leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. J Infect Dis 1988; 10: 560-586.
7. Davidson RN, Croft SL. Recent advances in the treatment of visceral leishmaniasis. Trans Roy Soc Trop Med Hyg 1993; 87: 130-131 and 141.
8. Badaro R, Falcoff E, Badaro FS et al. Treatment of visceral leishmaniasis with Pentavalent Antimony and IFN-gamma. N Engl J Med 1990; 322: 16-21.
9. Lothorlary O, Mechali D, Christiaens D, Gougerot Pocidalo M, Bradley M, Babinet P. IFN-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS. Rev Inf Dis 1990; 12: 370-371.
10. Oullette M, Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitology Today 1993; 9: 150-153.
11. Davidson RN, Di Martino RN, Gradoni L et al. Liposomal amphotericin B (Ambisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75-81.
12. Torre-Cisneros J, Vilanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17: 625-627.
13. Lazanas MC, Tsekes GA, Papandreou S et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7: 1018-1019.
14. Lopez Dupla M, Aguado AG, Uriol PL et al. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J Antimicrob Chemother 1993; 32: 657-659.
15. Croft SL, Neal RA, Rao LS. Liposomal and other drug delivery systems in the treatment of leishmaniasis. In: Hart DT, ed. Leishmaniasis: The current status and new strategies for control. New York: Plenum Press, 1989: 783-792.
16. Black CDV, Watson GJ, Ward RJ. The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans Roy Soc Trop Med Hyg 1977; 71: 550-552.
17. Lopez-Berestein G. Liposomal amphotericin B in the treatment of fungal infection. Ann Int Med 1986; 105: 130-131.
18. Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986; 30: 847-851.
19. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Agents Chemother 1991; 28 (Suppl. B): 111-118.
20. Gradoni L, Davidson RN, Orsini S, Betto P, Gambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Targeting 1993; 1: 311-316.
21. De Rossell RA, de Duran R de J, Rossell O, Rodriguez AM. Is leishmaniasis ever cured? Trans Roy Soc Trop Med Hyg 1992; 86; 251-253.